Mangoceuticals Accelerates Growth With New Testosterone Therapy Program

Mangoceuticals, Inc. ( (MGRX) ) has shared an announcement.

On February 19, 2026, Mangoceuticals reported strong early results from its newly launched all-inclusive injectable testosterone replacement therapy program, priced at $99 per month. The plan bundles doctor visits, consultations, lab work and medication, and is delivered through the company’s telemedicine platform to men seeking convenient hormone care.

Since launching in mid-December, month-over-month sales of the injectable TRT offering have climbed 336% while customer acquisition costs fell 54%, positioning TRT as Mangoceuticals’ primary growth driver. Management said it plans to build on this momentum by expanding both injectable and oral testosterone products, broadening its men’s health portfolio and strengthening its position in a global TRT market projected to grow steadily in coming years.

More about Mangoceuticals, Inc.

Mangoceuticals, Inc., which operates under the MangoRx and PeachesRx brands, develops, markets and sells men’s health and wellness products via a secure telemedicine platform. The company currently focuses on pharmaceutical-based treatments for erectile dysfunction, hair growth, hormone replacement therapies and weight management, with prescriptions reviewed by licensed providers and filled through a partner compounding pharmacy.

The business model emphasizes discreet, direct-to-consumer delivery of prescriptions to patients’ homes, aiming to simplify access to care while maintaining regulatory compliance. By leveraging telehealth, Mangoceuticals targets the growing market for convenient, online-managed men’s health solutions, with a particular strategic emphasis on hormone optimization and testosterone replacement therapy.

Average Trading Volume: 623,148

Technical Sentiment Signal: Sell

Current Market Cap: $6.19M

For an in-depth examination of MGRX stock, go to TipRanks’ Overview page.